{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"35"}]}],"title":"Number of responses"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"35"}]}],"title":"Week 12 (Day 84); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Week 12 (Day 84); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"35"}]}],"title":"Week 24 (Day 168); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Week 24 (Day 168); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"24"}]}],"title":"Week 48 (Day 336); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Week 48 (Day 336); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"}]}],"title":"Week 72 (Day 504); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Week 72 (Day 504); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"Week 96 (Day 672); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Week 96 (Day 672); With disease progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Duration of response (DOR) based on RECIST 1.1 is defined as the date of the first recorded response to the first date of documented disease progression. The overall number of responses and the number of participants with and without disease progression was assessed.","groups":[{"description":"Part 1: Participants received treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks\n\nPart 2: Participants also received pexidartinib at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of pexidartinib for oral administration","id":"OG000","title":"Pexidartinib Part 1 and Part 2"},{"description":"Participants that received placebo in part 1 and received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of pexidartinib for oral administration","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"},{"description":"All participants who received Pexidartinib in Part 1 and Part 2 as well as those who only received Pexidartinib in Part 2.","id":"OG002","title":"All Pexidartinib Treated"}],"paramType":"NUMBER","populationDescription":"The overall number of responses and the number of participants with and without disease progression were assessed in the ITT population, specifically among the Pexidartinib Part 1, Pexidartinib Part 2; Pexidartinib Part 2 only, All Pexidartinib Treated participants, . Participants randomized to Placebo Part 1 only were not analyzed.","reportingStatus":"POSTED","timeFrame":"By Week 96","title":"Number of Responders to Pexidartinib With and Without Disease Progression","type":"SECONDARY","unitOfMeasure":"participants"}